Chairman of the Board

Dr. Bing Li is currently the Managing Director of Fosun Group, in charge of oversea PE investment for healthcare sector. Previously, Dr. Li was the Vice President and General Manager for Fosunpharma International Department, leading the company’s oversea investment and M&A. Dr. Li joined Fosunpharma from Warburg Pincus, where he co-led Warburg Pincus healthcare practice in China during 2010-2014. Prior to it, Dr. Li was General Manager, GSK China Enterprise where he led the Enterprise Business Unit and overall BD/Strategy function for GSK China. Previously, Dr. Li also worked at global headquarter of Eli Lilly and advanced his career from multiple roles including strategic planning, business development and new product planning. Dr. Li also had work experiences at G.D. Searle and Hewlett Packard Medical Product Group.

Dr. Li led the completion of various investment deals in China healthcare field, including multiple JV and acquisition deals for GSK, $200+ Million private placements into three Chinese pharma/Biopharma companies for Warburg Pincus, and the recent acquisition of Ambrx Inc. by a Fosun-led consortium.

Dr. Li serves as the Chairman of the Board of Ambrx, and previously has served on the boards of Shenzhen GSK-Neptunes Biologics Inc, China Biologic Products Incorporation (Nesdaq: CBPO), Kunming Jida Pharmaceutical, and Zhejiang Weixin Biological Pharmaceutical.

Dr. Li received his Ph.D. degree in Biologic Science from the University of Rochester (1997), an MBA/MEM joint degree from Kellogg School of Management (1999), and a B.S degree from Fudan University (1990).